<DOC>
	<DOCNO>NCT02961829</DOCNO>
	<brief_summary>It become clear combination intervention desirable achieve HIV cure . Therefore investigator propose pilot proof concept study , use combination number different intervention eradicate residual plasma viremia decrease HIV reservoir . The investigator hypothesize , ( ) antiretroviral intensification use Maraviroc , and/or dolutegravir ( ii ) Dendritic Cell vaccination use autologous HIV , ( iii ) purge intervention use Class III HDACs , Sirtuin-1 , ( iv ) decrease ratio long-lived central memory ( TCM ) /transitional memory ( TTM ) CD4+ T-cells use Auranofin provide synergistic impact lead sterilize cure HIV infection . Results study may provide insightful evidence plan next step use efficacious combination intervention strategy towards HIV sterilize cure .</brief_summary>
	<brief_title>Multi Interventional Study Exploring HIV-1 Residual Replication : Step Towards HIV-1 Eradication Sterilizing Cure</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>&gt; 18 year old Documented HIV1 infection . Has voluntarily sign ICF . On HAART â‰¥ 2 year , without change 24 week immediately prior screening . HIV viral load &lt; 50 copies/mL , never &gt; 50 copies/mL 2 consecutive occasion last 2 year . CD4 count nadir . &gt; 350 cells/ mm3 Current CD4 count &gt; 500 cells/ mm3 . R5 HIV1 Screening define proviral DNA genotropism . A subject NOT eligible study participation he/she meet ANY follow criterion : Any evidence active AIDSdefining condition . Any significant acute medical illness past 8 week . Women pregnant breastfeeding . Use follow within 90 day prior entry : systemic cytotoxic chemotherapy ; investigational agent ; immunomodulators ( colonystimulating factor , growth factor , systemic corticosteroid , HIV vaccine , immune globulin , interleukin , interferon ) ; coumadin , warfarin , Coumadin derivative anticoagulant . Use agent definitely possibly associate effect QT interval : amiodarone , arsenic trioxide , astemizole , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide , dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , probucol , procainamide , quinidine , sotalol , sparfloxacin , terfenadine , thioridazine . Receipt compound HDAC inhibitorlike activity , valproic acid nicotinamide within last 30 day . Potential participant may enroll 30day washout period . Known hypersensitivity component gold salt , nicotinamide analog . Hepatitis B ( HBsAg + ) Hepatitis C ( HCV RNA + ) infection . Known renal insufficiency define calculated creatinine clearance ( Cockcroft Gault formula ) &lt; 60 mL/min . Subjects laboratory abnormality grade 3 4 following exception : pancreatic amylase , cholesterol , triglyceride , gamma glutamyl transpeptidase , bilirubin . Any condition , investigator opinion , could compromise subject 's safety adherence trial protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dendritic Cell vaccination use</keyword>
	<keyword>antiretroviral intensification</keyword>
	<keyword>Auranofin</keyword>
	<keyword>Histone Deacetylase Inhibitor</keyword>
	<keyword>residual viral replication</keyword>
	<keyword>HIV sanctuary</keyword>
	<keyword>HIV latency</keyword>
</DOC>